Abstract：Objective To evaluate the effect of Fasudil Hydrochloride combined with Cinepazide Maleate in the treatment of cerebral vasospasm(CVS) after aneurismal subarachnoid hemorrhage(aSAH), and to provide evidences for clinical treatment. Methods Seventy-two patients with CVS after aSAH were selected in the Nanchong Central Hospital from January 2016 to March 2017, and divided into control group and observation group by random number table method, with 36 cases in each group. The control group was treated with Fasudil Hydrochloride, and the observation group was treated with Cinepazide Maleate combined with Fasudil Hydrochloride, the levels of IL-6 before and after treatment, CT score, GOS Score, clinical efficacy, adverse events were compared between two groups. Results The levels of IL-6 were decreased significantly after treatment in two groups, and the observation group was significantly lower than the control group, with statistical significance (P ＜ 0.01). The CT score was negatively correlated with GOS score in the control group and observation group(r=-0.635, -0.741, P ＜ 0.05). The total effective rate of observation group(91.67%) was higher than that of control group (72.22%), with statistical significance (P ＜ 0.05). The incidence of adverse events was similar between two groups, with no statistical significance (P > 0.05). Conclusion Fasudil Hydrochloride combined with Cinepazide Maleate has significant therapeutic efficacy on CVS after aSAH, and can effectively inhibit inflammatory factors and reduce adverse events with good safety.
[1] Nakamura T，Matsui T，Hosono A，et al. Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH [J]. Acta Neurochir Suppl，2013，115（115）：81-85.
[2] 邢娟.法舒地尔联合尼莫地平治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的疗效[J].江苏医药，2014，40（1）：100-101.
[3] 冯怡墨，孙晓川，张晓东，等.依达拉奉联合马来酸桂哌齐特治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的临床观察[J].中国药房，2017，28（2）：230-232.
[4] Siasios I，Kapsalaki EZ，Fountas KN. Cerebral vasospasm pharmacological treatment：an update[J]. Neurol Res Int，2013，2013：571328.doi：10.1155/2013/571328.
[5] Saito A，Inoue M，Kon H，et al. Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage[J]. Acta Neurochir Suppl，2015，120（120）：297-301.
[6] Satoh S，Takayasu M，Kawasaki K，et al. Antivasospastic effects of hydroxyfasudil， a Rho-kinase inhibitor， after subarachnoid hemorrhage[J]. J Pharmacol Sci，2012，118（1）：92-98.
[7] 刘骏辉，陈谦学.动脉瘤性蛛网膜下腔出血后抗血管痉挛的药物治疗[J].中国临床神经外科杂志，2016，21（8）：504-507.
[8] 刘永飞，赵贵锋.动脉瘤蛛网膜下腔出血后脑血管痉挛药物治疗的研究进展[J].医学综述，2016，22（13）：2607-2612.
[9] Huang RQ，Jiang FG，Feng ZM，et al.Nicardipine in the treatment of aneurysmal subarachnoid haemorrhage：a meta-analysis of published data [J]. Acta Neurol Belg，2013， 113（1）：3-6.
[10] 秦丽娜.法舒地尔对蛛网膜下腔出血后脑血管痉挛的临床效果分析[J].河南医学研究，2017，26（2）：316-317.
[11] Zhao J，Zhou D，Guo J，et al.Efficacy and safety of fasudil in patients with subarachnoid hemorrhage： final results of a randomized trial of fasudil versus nimodipine[J]. Neurol Med Chir，2011，51（10）：679-683.
[12] Iwabuchi S，Hayashi M，Yokouchi T，et al.Prophylactic intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid haemorrhage[J]. Acta Neurochir Suppl，2015，120：167-169.
[13] 陈东，罗伟坚. 法舒地尔动、静脉给药治疗颅内动脉瘤栓塞后脑血管痉挛的对比研究[J].临床神经外科杂志，2014，11（3）：184-186.
[14] 李海玲.法舒地尔不同给药途径治疗颅内动脉瘤栓塞后脑血管痉挛对比研究[J].医药论坛杂志，2016，37（6）：26-27.
[15] 王传明，李巷，韩金玲，等.马来酸桂哌齐特对蛛网膜下腔出血后脑血管痉挛患者大脑中动脉血流动力学的影响[J].中国医学工程，2015，23（6）：153-155.
[16] 刘翠芬，王凤艳.马来酸桂哌齐特与尼莫地平治疗蛛网膜下隙出血后脑血管痉挛疗效对比研究[J].中国现代神经疾病杂志，2013，13（10）：897-900.
[17] 杨彬源，陈桂增，王本艳，等.马来酸桂哌齐特联合尼莫地平治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛疗效观察[J].海南医学，2017，28（6）：971-973.
[18] 陈业鹏.马来酸桂哌齐特与尼莫地平治疗蛛网膜下腔出血后脑血管痉挛的疗效对比[J].中国临床研究，2014， 27（2）：166-168.
[19] 罗刚，喻坚柏，龚金兵，等.马来酸桂哌齐特治疗自发性蛛网膜下腔出血的效果观察[J].海南医学研究，2015， 24（8）：38-39.
[20] Hasegawa S，Hasegawa Y，Miura M. Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage： A Comprehensive Review of Basic and Clinical Studies [J]. Curr Drug Deliv，2016，13（399）：1.
2018, Vol. 15 
京公网安备 11010502046598号